NASDAQ:LNTH - Lantheus Stock Price, Forecast & News

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus Holdings Inc (NASDAQ:LNTH) announced its earnings results on Tuesday, February, 25th. The medical equipment provider reported $0.34 EPS for the quarter, beating analysts' consensus estimates of $0.30 by $0.04. The medical equipment provider had revenue of $89.35 million for the quarter, compared to analysts' expectations of $90.62 million. Lantheus had a return on equity of 46.58% and a net margin of 10.02%. Lantheus's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.29 EPS. View Lantheus' Earnings History.

Lantheus is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Lantheus.

Lantheus updated its FY20 earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of $1.34 to $1.40 for the period, compared to the Thomson Reuters consensus estimate of $1.03. The company issued revenue guidance of $384 million to $390 million, compared to the consensus revenue estimate of $382.92 million.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.

Headlines about LNTH stock have been trending somewhat negative this week, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Lantheus earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Lantheus.

Lantheus saw a increase in short interest in January. As of January 15th, there was short interest totalling 1,400,000 shares, an increase of 14.8% from the December 31st total of 1,220,000 shares. Based on an average daily volume of 360,700 shares, the days-to-cover ratio is presently 3.9 days. Currently, 3.7% of the shares of the stock are short sold. View Lantheus' Current Options Chain.

Some companies that are related to Lantheus include Myriad Genetics (MYGN), Heska (HSKA), Intellia Therapeutics (NTLA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT), Trinity Biotech (TRIB), GeneNews (GNWSF), Arca Biopharma (ABIO) and Achieve Life Sciences (ACHV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include Mobileye (MBBYF), Energy Transfer LP Unit (ET), CBL & Associates Properties (CBL), Gerdau (GGB), Akorn (AKRX), Exelixis (EXEL), Paratek Pharmaceuticals (PRTK), NovaBay Pharmaceuticals (NBY), Anavex Life Sciences (AVXL) and Cara Therapeutics (CARA).

(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Lantheus' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (3.76%), Renaissance Technologies LLC (3.58%), Vaughan Nelson Investment Management L.P. (3.38%), LSV Asset Management (3.25%), Tamarack Advisers LP (1.66%) and Prudential Financial Inc. (1.61%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno, Timothy G Healey and Tudor Brown. View Institutional Ownership Trends for Lantheus.

LNTH stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Rice Hall James & Associates LLC, Renaissance Technologies LLC, Royce & Associates LP, Citigroup Inc., Tamarack Advisers LP, Alliancebernstein L.P. and AQR Capital Management LLC. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View Insider Buying and Selling for Lantheus.

LNTH stock was bought by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Russell Investments Group Ltd., Bank of Montreal Can, Prudential Financial Inc., Public Sector Pension Investment Board, Geode Capital Management LLC, First Trust Advisors LP and Great West Life Assurance Co. Can. View Insider Buying and Selling for Lantheus.

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LNTH stock can currently be purchased for approximately $16.30.

Lantheus has a market capitalization of $639.78 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.

The official website for Lantheus is http://www.lantheus.com/.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]